Navigation Links
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Date:9/5/2008

Update on the Regulatory Strategy for Belinostat in PTCL

COPENHAGEN, Denmark, September 5 /PRNewswire-FirstCall/ -- TopoTarget A/S (OMX: TOPO) announced that a positive reply from the FDA was received on a Special Protocol Assessment (SPA) for a phase III trial for belinostat in PTCL (Peripheral T-Celle Lymphoma). This pivotal trial is to enrol approximately 120 patients and is to begin in Q4 2008. In June Fast Track designation was granted for the development of belinostat in this indication which supports TopoTarget's rapid market entry strategy. There is currently no standard therapy approved for PTCL.

"This is very good news. We can now move belinostat into a pivotal phase III. With the SPA in place we have agreed on a design for our pivotal phase III trial with the FDA which will begin in Q4 of this year. In addition with the FDA's Fast Track designation received in June for the PTCL indication we can continue with our strategy of rapid market entry for belinostat in an area with a high unmet medical need." Said Professor, Peter Buhl Jensen, MD, CEO of TopoTarget.

Design

The phase III trial is an open-label, multicenter, single arm efficacy and safety trial in patients with relapsed or refractory peripheral T-cell lymphoma who have failed at least one prior systemic therapy. Approximately 120 patients (100 evaluable patients) will be enrolled. Patients will be treated with 1000 mg/m2 belinostat administered as a 30 minute IV infusion on days 1-5 of every 3-week cycle until there is disease progression or unmanageable treatment-related toxicities.

Rational

Belinostat is a small molecule class I and II histone deacetylase inhibitor (HDACi). HDACi's modulate gene expression within tumor cells, including tumor suppressor genes, leading to G1 and G2/M cell cycle arrest, induction of apoptosis (programmed cell death), inhibition of angiogenesis, immune modulation, and promotion of cellular differentiation. Clinic
'/>"/>

SOURCE TopoTarget
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
2. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
3. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
4. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
5. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
8. Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
9. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
10. QLT announces positive Health Canada decision on Aczone(R)
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Livermore, California (PRWEB) October 01, 2014 ... Reyes has assumed the 2014-15 chairmanship of the ... election as vice chair in 2012. , Reyes has ... projects. She joined LLNL in 2001 to pursue her ... analysis of inertial fusion energy power plant designs. Since ...
(Date:10/2/2014)... 02, 2014 Cystic fibrosis (CF) is ... and the gastrointestinal organs. In particular, very thick mucus ... is very difficult to clear, occludes the airways, and ... these patients frequently suffer from chronic biofilm infections, and ... a novel approach to treating the major challenges in ...
(Date:10/2/2014)... (PRWEB) October 02, 2014 IAL ... fourth edition of its report on the markets ... new edition examines the developments encountered in the ... both products. , Full Report With TOC ... the market trends driving the demand. The study ...
(Date:10/2/2014)... Lexington,Kentucky and Queens, New York (PRWEB) October 02, ... is pleased to announce funding received to ... pathway in Alzheimer’s disease. A grant award from ... Institute on Aging (NIA), National Institutes of Health ... as Novel AD Therapeutics." The company also received ...
Breaking Biology Technology:Susana Reyes Assumes Chair of American Nuclear Society Fusion Energy Division 2Synedgen to Present at North American Cystic Fibrosis Conference 2Synedgen to Present at North American Cystic Fibrosis Conference 3Global Overview of the Spray Polyurethane Foam (SPF) & One Component Foam (OCF) : Industry Analysis, Size, Share, Trends And Forecast Research Report by Researchmoz 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... a biotechnology company developing peptide therapeutics for metabolic diseases, ... as Chief Executive Officer. Dr. Gottesdiener joins Rhythm from ... President and Late-Stage Therapeutic Group Leader, with responsibility for ... and previously as head of early-stage clinical development programs. ...
... -- an open-source, web-based platform for data-intensive biomedical ... a "cloud computing" resource. A team of researchers ... and molecular biology at Penn State University; Kateryna ... State; and James Taylor from Emory University, developed ...
Cached Biology Technology:Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Rhythm Names Keith M. Gottesdiener Chief Executive Officer 2Galaxy DNA-analysis software is now available 'in the cloud' 2Galaxy DNA-analysis software is now available 'in the cloud' 3
(Date:10/2/2014)... , October 2, 2014 ... Event for payment, identification and mobility which is ... from 4 to 6 November 2014, is proud ... partnership with innovation agency FABERNOVEL.   ... this initiative is to support innovative businesses from ...
(Date:10/2/2014)... SHELTON, Conn. , Oct. 2, 2014 NXT-ID, ... focused on the growing mobile commerce market, announces the airings ... Money and Mad Money. The national ads resumed ... will air October 2 nd and October 3 rd ... The continuing ads that began airing on CNBC ...
(Date:10/2/2014)... CARTES SECURE CONNEXIONS 2014 Conference: A Step Ahead ... SECURE CONNEXIONS 2014 is being held at Paris Nord ... This 29 th  international meeting for the digital security ... together the global community of a constantly evolving sector. ... will set the pace for the event.   ...
Breaking Biology News(10 mins):CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 2CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 3CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 4CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 5CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 2CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 2CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 4
... in Acta Obstetricia et Gynecologica Scandinavica , a ... and Gynecology, indicate that human error is the most ... monitoring, lack of clinical skills, and failure to obtain ... Norwegian compensation claims following birth asphyxia. In ...
... we wanted to count the number of people in a crowd, ... imprecise, or we could ask each person to pass through a ... for creating a "DNA reader" that is able to detect the ... with integrated graphene transistor. The DNA molecules are diluted in ...
... team has discovered a gene associated with a high ... may be an actual cause of this form of ... "Because asthma is a complex disease, with multiple ... asthma occurring between ages two and six," said co-lead ...
Cached Biology News:Human error most common cause of birth asphyxia 2Graphene nanoribbons for 'reading' DNA 2Novel gene variant found in severe childhood asthma 2
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Reactivity: Human...
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: